Search
Clinician Ordering Portal
In this case, a more accurate assessment of the state of disease was attained through 40-GEP testing. Traditional staging methods, including AJCC8 and BWH, overestimated our patient’s risk profile. More research needs to be completed surrounding gene testing and metastatic risk. Our goal with this case is to contribute to the growing body of literature surrounding the use of gene expression profile testing in cutaneous cancer.
Scientific evidence
A physician’s guide to the use of gene expression profile ancillary diagnostic testing for cutaneous melanocytic neoplasms
Dec 2023
A real-world assessment of common use scenarios of MyPath GEP testing by dermatopathologists and dermatologists to achieve definitive diagnoses and personalized patient management plans.
Publication: Journal of Clinical and Aesthetic Dermatology
Incorporating a prognostic gene expression profile test into the mangement of cutaneous squamous cell carcinoma: An expert consensus panel report
Dec 2023
The 40-GEP test provides accurate and independent prognostic information beyond standard staging systems that only incorporate pathologic data. In this consensus paper, 8 dermatologists with significant expertise in diagnosing and managing cSCC concluded that incorporation of GEP testing into national guidelines can help further stratify patients based on risk of metastasis, and thus may improve morbidity and mortality.
Publication: Journal of Drugs in Dermatology
Performance of the 23-gene expression profile (23-GEP) test by histopathological evaluation in an independent, multi-center performance cohort of cutaneous melanocytic neoplasms
Nov 2023
Accuracy data in an independent, multi-center cohort of 2512 melanocytic lesions
Publication: Skin
A Tissue Systems Pathology Test Outperforms the Standard of Care Variables in Predicting Progression in Patients with Barrett’s Esophagus
Nov 2023
This study evaluated the predictive performance of TissueCypher versus current clinicopathologic variables in a multi-center cohort of BE patients.
Publication: Clinical and Translational Gastroenterology
The tissue systems pathology test outperforms pathology review in risk-stratifying patients with low-grade dysplasia
Nov 2023
This study aimed to compare the risk stratification performance of the TissueCypher test vs benchmarks of generalist and expert pathology.
Publication: Gastroenterology
An Automated Tissue Systems Pathology Test Can Standardize the Management and Improve Health Outcomes for Patients with Barrett's Esophagus
Nov 2023
Management guided by the TissueCypher test can standardize care plans by increasing the early detection of progressors who can receive therapeutic interventions, while also increasing the percentage of nonprogressors who can avoid unnecessary therapy and be managed by surveillance alone.
Publication: American Journal of Gastroenterology
A Tissue Systems Pathology Test Outperforms the Standard-of-Care Variables in Predicting Progression in Patients with Barrett’s Esophagus
Nov 2023
This study evaluated the predictive performance of TissueCypher versus current clinicopathologic variables in a multi-center cohort of BE patients.
Publication: Clinical and Translational Gastroenterology
Performance of the 23-gene expression profile (23-GEP) test by histopathological evaluation in an independent, multi center performance cohort of cutaneous melanocytic neoplasms
Oct 2023
Publication: Poster, presented at the 2023 ASDP Annual Meeting
The tissue systems pathology test predicts risk of progression in Medicare-eligible patients with Barrett’s esophagus
Oct 2023
TissueCypher risk-stratifies BE patients ≥ 65 years old independently of clinicopathologic variables and has significantly higher sensitivity for detection of progressors than pathology diagnosis of LGD.
Publication: Poster presentation (S599) at ACG 2023, Vancouver
The tissue systems pathology test objectively risk-stratifies patients with Barrett’s esophagus: a multicenter US clinical experience study
Oct 2023
TissueCypher risk-stratifies BE patients ≥ 65 years old independently of clinicopathologic variables and has significantly higher sensitivity for detection of progressors than pathology diagnosis of LGD.
Publication: Poster presentation (S600) at ACG 2023, Vancouver
40-gene expression profile representative of metastatic risk of squamous cell carcinoma in a Mohs surgical patient
Oct 2023
Publication: Cureus
Gene expression differences identified in skin samples of early-stage mycosis fungoides, atopic dermatitis, and psoriasis
Oct 2023
Publication: Poster, presented at the 2023 Fall Clinical Dermatology Conference®, Las Vegas, Nevada, October 19-22, 2023